Logotipo do repositório
 

Publicação:
Metabolic Syndrome Criteria As Predictors of Insulin Resistance, Inflammation and Mortality in Chronic Hemodialysis Patients

dc.contributor.authorVogt, Barbara Perez [UNESP]
dc.contributor.authorSouza, Priscilla L. [UNESP]
dc.contributor.authorMinicucci, Marcos Ferreira [UNESP]
dc.contributor.authorMartin, Luis Cuadrado [UNESP]
dc.contributor.authorBarretti, Pasqual [UNESP]
dc.contributor.authorCaramori, Jacqueline Socorro Costa Teixeira [UNESP]
dc.contributor.institutionUniversidade Estadual Paulista (Unesp)
dc.date.accessioned2015-03-18T15:54:42Z
dc.date.available2015-03-18T15:54:42Z
dc.date.issued2014-10-01
dc.description.abstractBackground: Chronic kidney disease (CKD) and metabolic syndrome are characterized by overlapping disorders, including glucose intolerance, hypertension, dyslipidemia, and, in some cases, obesity. However, there are no specific criteria for the diagnosis of metabolic syndrome in CKD. Metabolic syndrome can also be associated with increased risk of mortality. Some traditional risk factors may protect dialysis patients from mortality, known as "reverse epidemiology." Metabolic syndrome might undergo reverse epidemiology. The objectives were to detect differences in frequency and metabolic characteristics associated with three sets of diagnostic criteria for metabolic syndrome, to evaluate the accuracy of insulin resistance (IR) and inflammation to identify patients with metabolic syndrome, and to investigate the effects of metabolic syndrome by three sets of diagnostic criteria on mortality in chronic hemodialysis patients.Methods: An observational study was conducted. Diagnostic criteria for metabolic syndrome proposed by National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III), International Diabetes Federation (IDF), and Harmonizing the Metabolic Syndrome (HMetS) statement were applied to 98 hemodialysis patients.Results: The prevalence of metabolic syndrome was 51%, 66.3%, and 75.3% according to NCEP ATP III, IDF, and HMetS criteria, respectively. Diagnosis of metabolic syndrome by HMetS was simultaneously capable of revealing both inflammation and IR, whereas NCEP ATP III and IDF criteria were only able to identify IR. Mortality risk increased in the presence of metabolic syndrome regardless of the criteria used.Conclusions: The prevalence of metabolic syndrome in hemodialysis varies according to the diagnostic criteria used. IR and inflammation predict metabolic syndrome only when diagnosed by HMetS criteria. HMetS was the diagnostic criteria that can predict the highest risk of mortality.en
dc.description.affiliationUniv Estadual Paulista, UNESP, Fac Med Botucatu, Dept Internal Med, BR-18618970 Sao Paulo, Brazil
dc.description.affiliationUniv Estadual Paulista, UNESP, Inst Biociencias Botucatu, BR-18618970 Sao Paulo, Brazil
dc.description.affiliationUnespUniv Estadual Paulista, UNESP, Fac Med Botucatu, Dept Internal Med, BR-18618970 Sao Paulo, Brazil
dc.description.affiliationUnespUniv Estadual Paulista, UNESP, Inst Biociencias Botucatu, BR-18618970 Sao Paulo, Brazil
dc.description.sponsorshipCoordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)
dc.format.extent443-449
dc.identifierhttp://dx.doi.org/10.1089/met.2014.0011
dc.identifier.citationMetabolic Syndrome And Related Disorders. New Rochelle: Mary Ann Liebert, Inc, v. 12, n. 8, p. 443-449, 2014.
dc.identifier.doi10.1089/met.2014.0011
dc.identifier.issn1540-4196
dc.identifier.lattes5496411983893479
dc.identifier.lattes4923203168446615
dc.identifier.lattes7438704034471673
dc.identifier.orcid0000-0003-4979-4836
dc.identifier.urihttp://hdl.handle.net/11449/116994
dc.identifier.wosWOS:000342152500006
dc.language.isoeng
dc.publisherMary Ann Liebert, Inc
dc.relation.ispartofMetabolic Syndrome And Related Disorders
dc.relation.ispartofjcr1.744
dc.relation.ispartofsjr0,837
dc.rights.accessRightsAcesso restrito
dc.sourceWeb of Science
dc.titleMetabolic Syndrome Criteria As Predictors of Insulin Resistance, Inflammation and Mortality in Chronic Hemodialysis Patientsen
dc.typeArtigo
dcterms.rightsHolderMary Ann Liebert, Inc
dspace.entity.typePublication
unesp.author.lattes5496411983893479[5]
unesp.author.lattes4923203168446615
unesp.author.lattes7438704034471673
unesp.author.orcid0000-0003-4979-4836[5]
unesp.author.orcid0000-0002-5980-4367[3]
unesp.campusUniversidade Estadual Paulista (UNESP), Faculdade de Medicina, Botucatupt
unesp.departmentClínica Médica - FMBpt

Arquivos